中東およびアフリカの迷走神経刺激市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2022 –2029 |
 市場規模（基準年） |
USD 55.39 Million |
 Market Size (Forecast Year) |
USD 76.13 Million |
 CAGR |
% |
| 主要市場プレーヤー |
中東およびアフリカの迷走神経刺激市場、製品タイプ別（埋め込み型迷走神経刺激装置および外部迷走神経刺激装置）、生体材料別（セラミック、金属、ポリマー）、用途別（疼痛管理、てんかん発作、肥満管理、うつ病および不安症、その他）、患者タイプ別（成人、小児、高齢者）、エンドユーザー別（病院、外来手術センター、専門センター、その他）、流通チャネル別（直接入札、小売販売、その他）業界動向および2029年までの予測。
中東およびアフリカの迷走神経刺激市場の分析と洞察
迷走神経は、代謝恒常性を調節する自律神経系の重要な構成要素であり、求心性および遠心性の経路を介して恒常性を維持する神経内分泌免疫軸の重要な構成要素として機能します。手動または電気刺激を含む迷走神経を刺激するあらゆるアプローチは、迷走神経刺激 (VNS) と呼ばれます。難治性てんかんおよび治療抵抗性うつ病の場合、左頸部 VNS は承認された治療法です。
WHO によると、神経疾患は世界中の全疾病の 4.5% ～ 11% を占めています。迷走神経刺激装置は、てんかん、うつ病、喘息、心血管疾患を患う患者の治療にも使用されています。
中東およびアフリカの迷走神経刺激市場は、2022年から2029年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に4.1％のCAGRで成長し、2021年の5,539万米ドルから2029年には7,613万米ドルに達すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 (2019 - 2014 にカスタマイズ可能) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
製品タイプ別（埋め込み型 VNS デバイスおよび外部 VNS デバイス）、生体材料別（セラミック、金属、ポリマー）、用途別（疼痛管理、てんかん発作、肥満管理、うつ病および不安症、その他）、患者タイプ別（成人、小児、高齢者）、エンドユーザー別（病院、外来手術センター、専門センター、その他）。 |
|
対象国 |
南アフリカ、UAE、エジプト、サウジアラビア、イスラエル、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
Medtronic、LivaNova PLC、electroCore, Inc.、Soterix Medical Inc.、SetPoint Medical、MicroTransponder Inc、Parasym Ltd、tVNS Technologies GmbH など。 |
市場定義: 中東およびアフリカの迷走神経刺激市場
The vagus nerve is a long cranial nerve that runs from a person’s brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates body functions while a person is at rest. It delivers messages to a person’s brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a person’s ears, sinuses, and esophagus as well.
VNS involves a pulse generator inserted under a person’s skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individual’s physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation.
Market Dynamics: Middle East and Africa Vagus Nerve Stimulation Market
Drivers
- Increasing prevalence and incidence of neurological disorders
Neurological disorders cause 4.5% to 11% of all illnesses, whether in low or high-income countries. The impact is greater compared to that of malignancies, gastrointestinal diseases, or respiratory illnesses, and it is expected to grow over the next years. One of the most common neurological conditions, epilepsy, affects almost every country on earth. Most people with this illness are seen in high-population countries. Due to this rising prevalence, there is a rising demand for a variety of tools and treatments, such as VNS. More neurological problems are being treated with VNS. In addition to other clinical uses, it aids in the treatment of neurological conditions like epilepsy and depression due to the significant prevalence of neurological conditions worldwide.
- Innovative non-invasive vagus nerve stimulation devices introduced to meet demand
Traditional and conventional VNS devices are implanted in the patient's body and leads are placed on the vagus nerves that provide electrical stimulation when required. Growing demand and technological advancement of innovative devices lead to the introduction of small-sized implantable VNS devices in the market. These small-sized implantable devices offer various clinical benefits to patients and healthcare providers. The introduction of innovative devices is anticipated to boost the market growth.
Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices
- Rise in product approvals
The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).
For instance,
-
The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Middle East and Africa, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.
The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the Middle East and Africa region. Hence, the rise in product approvals is expected to propel market growth.
-
Product development in recent years
Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.
Opportunities
-
Strategic initiatives by the key market players
The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.
The companies operating Middle East and Africa in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market
-
Rising government initiatives for neurological disease
The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.
Restraint/Challenge
- High maintenance and device costs to restrain adoption of vagus nerve stimulators
The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.
Post-COVID-19 Impact on Middle East and Africa Vagus Nerve Stimulation Market
The COVID-19 outbreak had a drastic effect on Middle East and Africa healthcare with a number of countries severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.
Recent Development
- In May 2022, electroCore, Inc. announced that the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be available in 130 National Spine and Pain Centers (NSPC) affiliated locations across the U.S. for patients suffering from pain associated with different forms of primary headache. This would help the organization to develop more revenue.
Middle East and Africa Vagus Nerve Stimulation Market Scope
Middle East and Africa vagus nerve stimulation market is segmented into product type, biomaterial, application, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Implantable VNS Devices
- External VNS Devices
製品タイプに基づいて、市場は埋め込み型 VNS デバイスと外部 VNS デバイスに分類されます。
生体材料
- 陶芸
- メタリック
- ポリマー
生体材料に基づいて、市場はセラミック、金属、ポリマーに分類されます。
応用
- 疼痛管理
- てんかん発作
- 肥満管理
- うつ病と不安
- その他
用途に基づいて、市場は疼痛管理、てんかん発作、肥満管理、うつ病および不安症、その他に分類されます。
患者タイプ
- 大人
- 小児科
- 老年病
患者の種類に基づいて、市場は成人、小児、高齢者に分類されます。
エンドユーザー
- 病院
- 外来手術センター
- 専門センター
- その他
エンドユーザーに基づいて、市場は病院、外来手術センター、専門センター、その他に分類されます。
流通チャネル
- 直接入札
- 小売販売
- その他
流通チャネルに基づいて、市場は直接入札、小売販売、その他に分類されます。
中東およびアフリカの迷走神経刺激市場の地域分析/洞察
中東およびアフリカの迷走神経刺激市場が分析され、市場規模の洞察と傾向が、上記のように国、製品タイプ、生体材料、用途、患者タイプ、エンドユーザー、流通チャネル別に提供されます。
南アフリカは、市場シェアと収益の面で中東およびアフリカの迷走神経刺激市場を支配しており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域における神経疾患の有病率と発症率が高いことによるもので、研究開発投資の増加と新製品の発売が市場の成長を後押ししています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、中東およびアフリカのブランドの存在と入手可能性、地元および国内ブランドとの競争により直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
競争環境と中東およびアフリカの迷走神経刺激市場シェア分析
中東およびアフリカの迷走神経刺激市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、中東およびアフリカでのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。
この市場で活動している主要企業としては、Medtronic、LivaNova PLC、electroCore, Inc.、Soterix Medical Inc.、SetPoint Medical、MicroTransponder Inc、Parasym Ltd、tVNS Technologies GmbH などがあります。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、MEA と地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 LIFELINE CURVE , BY PRODUCT TYPE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 KEY STRATEGIC INITIATIVES
5 REGULATIONS OF MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND
6.1.3 RISE IN PRODUCT APPROVALS
6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS
6.2 RESTRAINTS
6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS
6.2.2 RISE IN PRODUCT RECALL
6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES
7 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 IMPLANTABLE VNS DEVICE
7.3 EXTERNAL VNS DEVICE
8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL
8.1 OVERVIEW
8.2 METALLIC
8.3 POLYMERIC
8.4 CERAMICS
9 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 EPILEPTIC SEIZURES
9.2.1 IMPLANTABLE VNS DEVICE
9.2.2 EXTERNAL VNS DEVICE
9.3 DEPRESSION AND ANXIETY
9.3.1 IMPLANTABLE VNS DEVICE
9.3.2 EXTERNAL VNS DEVICE
9.4 PAIN MANAGEMENT
9.4.1 IMPLANTABLE VNS DEVICE
9.4.2 EXTERNAL VNS DEVICE
9.5 OBESITY MANAGEMENT
9.5.1 IMPLANTABLE VNS DEVICE
9.5.2 EXTERNAL VNS DEVICE
9.6 OTHERS
10 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.2.1 IMPLANTABLE VNS DEVICES
10.2.2 EXTERNAL VNS DEVICES
10.3 GERIATRIC
10.3.1 IMPLANTABLE VNS DEVICES
10.3.2 EXTERNAL VNS DEVICES
10.4 PEDIATRIC
10.4.1 IMPLANTABLE VNS DEVICES
10.4.2 EXTERNAL VNS DEVICES
11 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER
11.1 OVERVIEW
11.2 SPECIALTY CENTERS
11.3 HOSPITALS
11.4 AMBULATORY SURGICAL CENTERS (ASCS)
11.5 OTHERS
12 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY REGION
13.1 MIDDLE EAST AND AFRICA
13.1.1 SOUTH AFRICA
13.1.2 UAE
13.1.3 EGYPT
13.1.4 SAUDI ARABIA
13.1.5 ISRAEL
13.1.6 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ELECTROCORE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 LIVANOVA PLC
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 MEDTRONIC
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 SETPOINT MEDICAL
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 TVNS TECHNOLOGIES GMBH
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NEUROPIX COMPANY LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BRAIN CONTROL CO. LTD
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 CIRTEC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 MICROTRANSPONDER INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 PARASYM LTD
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 RESHAPE LIFESCIENCES INC. (2021)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 SOTERIX MEDICAL INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 37 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 38 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 52 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 53 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 SOUTH AFRICA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 66 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 67 UAE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 68 UAE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 69 UAE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 UAE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 UAE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 UAE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 UAE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 UAE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 UAE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 UAE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 UAE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 78 UAE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 UAE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 82 EGYPT VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 83 EGYPT VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 84 EGYPT VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 EGYPT EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 EGYPT DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 EGYPT PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 EGYPT OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 EGYPT VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 90 EGYPT ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 EGYPT GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 EGYPT PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 EGYPT VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 EGYPT VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 96 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 97 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 98 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 99 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 100 SAUDI ARABIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 101 SAUDI ARABIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 102 SAUDI ARABIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 SAUDI ARABIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 104 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 SAUDI ARABIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 SAUDI ARABIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 SAUDI ARABIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 108 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 SAUDI ARABIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 112 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 113 ISRAEL VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 ISRAEL PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 ISRAEL OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 ISRAEL VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 ISRAEL ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 ISRAEL GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 ISRAEL PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 ISRAEL VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 ISRAEL VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 126 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 127 REST OF MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR INNOVATIVE NON–INVASIVE VAGUS STIMULATION DEVICES AND THE INCREASED PREVALENCE OF NEUROLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMPLANTABLE VNS DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET
FIGURE 14 INCIDENCE OF ADULT-ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 15 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2021
FIGURE 16 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2021
FIGURE 20 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2021
FIGURE 24 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2021
FIGURE 28 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, 2021
FIGURE 32 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 40 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 41 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 MIDDLE EAST AND AFRICA VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 44 MIDDLE EAST & AFRICA VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
